New combo therapy aims to keep aggressive lung cancer at bay
NCT ID NCT07459634
Summary
This study is testing whether a combination of two drugs, lurbinectedin and durvalumab, can help control extensive-stage small cell lung cancer after initial chemotherapy. It is for patients whose cancer has not gotten worse after their first round of treatment. The main goal is to see if this maintenance therapy can delay the cancer from progressing again.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Valkyrie Clinical Trials, Inc.
Los Angeles, California, 90067, United States
Conditions
Explore the condition pages connected to this study.